News

Filter

Current filters:

AlkermesNeurological

1 to 9 of 13 results

Alkermes files NDA for aripiprazole lauroxil in schizophrenia

Alkermes files NDA for aripiprazole lauroxil in schizophrenia

26-08-2014

Ireland-headquartered biotech firm Alkermes has submitted a New Drug Application to the US Food and Drug…

AbilifyAlkermesaripiprazole lauroxilBiotechnologyNeurologicalRegulationUSA

Alkermes leaps on positive Ph III results for aripiprazole lauroxil for schizophrenia

Alkermes leaps on positive Ph III results for aripiprazole lauroxil for schizophrenia

09-04-2014

US biotech firm Alkermes saw its shares spike on Tuesday, after it announced positive top-line results…

AbilifyAlkermesaripiprazole lauroxilBiotechnologyLundbeckNeurologicalOtsukaRegulationResearch

Alkermes reveals candidates for MS, cancer and pain

18-07-2013

US drugmaker Alkermes (Nasdaq: ALKS) has unveiled three new drug candidates for the treatment of multiple…

AlkermesBiogen IdecNeurologicalNorth AmericaOncologyPharmaceuticalResearchTecfidera

Alkermes boosted by positive Ph II data on ALKS 5461 for major depressive disorder

18-04-2013

Ireland-headquartered Alkermes (Nasdaq: ALKS) saw its shares rise 16% to $29.72, after it announced positive…

AlkermesNeurologicalPharmaceuticalResearch

FDA approves Otsuka and Lundbeck's once-monthly Abilify Maintena for schizophrenia

01-03-2013

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578) and Danish partner Lundbeck (LUND: DC) have received…

Abilify MaintenaAlkermesLundbeckNeurologicalNorth AmericaOtsukaPharmaceuticalRegulation

Alkermes and J&J initiate Ph III trial of three-month Invega Sustenna

12-06-2012

USA-based Alkermes (Nasdaq: ALKS) and partner health care giant Johnson & Johnson (NYSE: JNJ) have started…

AlkermesInvega SustennaJohnson & JohnsonNeurologicalPharmaceuticalResearch

Strong results for Alkermes’ ALKS 5461 in major depressive disorder

04-01-2012

US drugmaker Alkermes (Nasdaq: ALKS) yesterday released positive early clinical results for a central…

AlkermesAripiprazoleNeurologicalPharmaceuticalResearch

Alkermes updates analysts and investors on outlook and product portfolio

19-07-2011

USA-based Alkermes (Nasdaq: ALKS) “will be a dramatically different company, with a broad portfolio…

AlkermesFinancialNeurologicalPharmaceuticalResearch

1 to 9 of 13 results

COMPANY SPOTLIGHT

Menarini

Back to top